These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 24080498

  • 1. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
    Sarfo FS, Zhang Y, Egan D, Tetteh LA, Phillips R, Bedu-Addo G, Sarfo MA, Khoo S, Owen A, Chadwick DR.
    J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
    [Abstract] [Full Text] [Related]

  • 2. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients.
    Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH.
    AIDS; 2009 Oct 23; 23(16):2101-6. PubMed ID: 19779319
    [Abstract] [Full Text] [Related]

  • 3. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH.
    J Antimicrob Chemother; 2014 Aug 23; 69(8):2175-82. PubMed ID: 24729586
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, Maartens G, Haas DW.
    Br J Clin Pharmacol; 2015 Jul 23; 80(1):146-56. PubMed ID: 25611810
    [Abstract] [Full Text] [Related]

  • 6. Meta-analysis of the effect of CYP2B6, CYP2A6, UGT2B7 and CAR polymorphisms on efavirenz plasma concentrations.
    Ayuso P, Neary M, Chiong J, Owen A.
    J Antimicrob Chemother; 2019 Nov 01; 74(11):3281-3290. PubMed ID: 31369088
    [Abstract] [Full Text] [Related]

  • 7. High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.
    Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C.
    Pharmacogenet Genomics; 2013 Aug 01; 23(8):415-27. PubMed ID: 23778320
    [Abstract] [Full Text] [Related]

  • 8. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
    Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW.
    Pharmacogenet Genomics; 2012 Dec 01; 22(12):858-67. PubMed ID: 23080225
    [Abstract] [Full Text] [Related]

  • 9. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
    Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A, German Competence Network for HIV/AIDS Coordinators.
    J Antimicrob Chemother; 2011 Sep 01; 66(9):2092-8. PubMed ID: 21715435
    [Abstract] [Full Text] [Related]

  • 10. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
    Ngaimisi E, Habtewold A, Minzi O, Makonnen E, Mugusi S, Amogne W, Yimer G, Riedel KD, Janabi M, Aderaye G, Mugusi F, Bertilsson L, Aklillu E, Burhenne J.
    PLoS One; 2013 Sep 01; 8(7):e67946. PubMed ID: 23861838
    [Abstract] [Full Text] [Related]

  • 11. Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.
    Sukasem C, Cressey TR, Prapaithong P, Tawon Y, Pasomsub E, Srichunrusami C, Jantararoungtong T, Lallement M, Chantratita W.
    Br J Clin Pharmacol; 2012 Dec 01; 74(6):1005-12. PubMed ID: 22471906
    [Abstract] [Full Text] [Related]

  • 12. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
    Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A, German Competence Network for HIV/AIDS.
    J Antimicrob Chemother; 2008 Apr 01; 61(4):914-8. PubMed ID: 18281305
    [Abstract] [Full Text] [Related]

  • 13. Effects of cytochrome P450 2B6 and constitutive androstane receptor genetic variation on Efavirenz plasma concentrations among HIV patients in Kenya.
    Ngayo MO, Oluka M, Kwena ZA, Bulimo WD, Okalebo FA.
    PLoS One; 2022 Apr 01; 17(3):e0260872. PubMed ID: 35235559
    [Abstract] [Full Text] [Related]

  • 14. CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients.
    Olagunju A, Siccardi M, Amara A, Jevtovic D, Kusic J, Owen A, Dragovic G.
    Ther Drug Monit; 2014 Dec 01; 36(6):734-8. PubMed ID: 24831655
    [Abstract] [Full Text] [Related]

  • 15. High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections.
    Sukasem C, Chamnanphon M, Koomdee N, Puangpetch A, Santon S, Jantararoungtong T, Prommas S, Chantratita W, Manosuthi W.
    Drug Metab Pharmacokinet; 2013 Dec 01; 28(5):391-7. PubMed ID: 23399569
    [Abstract] [Full Text] [Related]

  • 16. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
    Manosuthi W, Sukasem C, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.
    Antimicrob Agents Chemother; 2014 Dec 01; 58(4):2268-73. PubMed ID: 24492364
    [Abstract] [Full Text] [Related]

  • 17. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
    Manosuthi W, Sukasem C, Lueangniyomkul A, Mankatitham W, Thongyen S, Nilkamhang S, Manosuthi S, Sungkanuparph S.
    Antimicrob Agents Chemother; 2013 Feb 01; 57(2):1019-24. PubMed ID: 23254426
    [Abstract] [Full Text] [Related]

  • 18. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
    Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y.
    Eur J Clin Pharmacol; 2012 Mar 01; 68(3):267-71. PubMed ID: 21901344
    [Abstract] [Full Text] [Related]

  • 19. Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor.
    Cortes CP, Siccardi M, Chaikan A, Owen A, Zhang G, la Porte CJ.
    Ther Drug Monit; 2013 Feb 01; 35(1):78-83. PubMed ID: 23172109
    [Abstract] [Full Text] [Related]

  • 20. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
    Leger P, Dillingham R, Beauharnais CA, Kashuba AD, Rezk NL, Fitzgerald DW, Pape JW, Haas DW.
    J Infect Dis; 2009 Sep 15; 200(6):955-64. PubMed ID: 19659438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.